SCHEMBL5578324

SCHEMBL5578324

Brc1ccc2nc3c(c(NCc4ccccc4)c2c1)CCN3Cc1ccccc1

nearest known ligand 0.72

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 7/20 0.72
ALDH1A1 P00352 6/20 0.72
KMT2A Q03164 6/20 0.72
LMNA P02545 4/20 0.72
MAPT P10636 3/20 0.72
MITF O75030 1/20 0.48
ALPG P10696 1/20 0.48
MEN1 O00255 5/20 0.48
HPGD P15428 3/20 0.48
SMN1; SMN2 Q16637 2/20 0.48
GAA P10253 2/20 0.48
HTT P42858 3/20 0.46
ACHE P22303 4/20 0.46
PDE5A O76074 5/20 0.46
HSD17B10 Q99714 1/20 0.46
AKR1B10 O60218 1/20 0.45
AKR1A1 P14550 1/20 0.45
AKR1B1 P15121 1/20 0.45
POLB P06746 1/20 0.44
TDP1 Q9NUW8 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5578063 0.89 KDM4E (0.72) KDM4EALDH1A1KMT2ALMNAMAPT
SCHEMBL5577949 0.87 KDM4E (0.67) KDM4EALDH1A1KMT2ALMNAMAPT
SCHEMBL5578267 0.84 KDM4E (1.00) KDM4EALDH1A1KMT2ALMNAMAPT
SCHEMBL5578144 0.80 KDM4E (0.72) KDM4EALDH1A1KMT2ALMNAMAPT
SCHEMBL6791224 0.80 KMT2A (0.55) KDM4EALDH1A1KMT2ALMNAMAPT
SCHEMBL5577942 0.79 KDM4E (0.71) KDM4EALDH1A1KMT2ALMNAMAPT
SCHEMBL6780670 0.78 KMT2A (0.53) KDM4EALDH1A1KMT2ALMNAMAPT
SCHEMBL6785863 0.77 KMT2A (0.52) KDM4EALDH1A1KMT2ALMNAMAPT
Hydrochloric Acid SCHEMBL5579198 0.76 KDM4E (0.85) KDM4EALDH1A1KMT2ALMNAMAPT
SCHEMBL5578145 0.76 KDM4E (0.66) KDM4EALDH1A1KMT2ALMNAMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070232538-A1 Uses of polypeptides TAKEDA PHARMACEUTICAL COMPANY, LTD (JP) 2007-10-04 US disclosed
US-20040053826-A1 Uses of polypeptides TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2004-03-18 US disclosed
EP-1308513-A1 USE OF POLYPEPTIDE Takeda Chemical Industries, Ltd. (JP) 2003-05-07 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070232538-A1 Uses of polypeptides NPSR1, SCTR, GRPR KDM4E 4438/4885ALDH1A1 3946/4885KMT2A 2960/4885
US-20040053826-A1 Uses of polypeptides NPSR1, SCTR, GRPR KDM4E 4438/4885ALDH1A1 3946/4885KMT2A 2960/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.